Second Locoregional Recurrence Predicts Survival Among Patients With Sarcoma
Researchers reported outcomes for patients who underwent a second resection after disease recurrence.
Researchers reported outcomes for patients who underwent a second resection after disease recurrence.
Trabectedin, an alkylating agent, removes tumor growth-promoting M2 macrophages, leading to more effective natural killer T cell activity.
For an ongoing phase 2 trial, researchers are recruiting 30 patients with advanced or metastatic sarcoma to receive the drug combination.
In an ongoing phase 2 study, researchers are evaluating the safety and efficacy of a 5-day hypofractionated radiotherapy course.
Institutional policies determine whether cancers are coded by disease type or organ site, which can lead to miscalculations of the global burden of a particular cancer type.